Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

Post TAVR Cognitive Function at Short Term: Better or Worse?

There is little information on the short and mid-term evolution of cognitive function after transcatheter aortic valve...
solaci -
Learn More
Antithrombotic Anticoagulants

Apixaban: An Alternative for Patients with Atrial Fibrillation Undergoing TAVR?

Courtesy of Dr. Carlos Fava. The prevalence of atrial fibrillation in patients undergoing transcatheter aortic valve replacement (TAVR) is...
solaci -
Learn More
Structural heart disease

TAVR in Low-Flow Low-Gradient Aortic Stenosis and Severe Impairment of Systolic Function

Patients with low-flow, low-gradient severe symptomatic aortic stenosis associated with severe impairment of the left ventricular systolic...
solaci -
Learn More
Structural heart disease

Permanent Pacemaker Predictors with SAPIEN 3

The aim of this study was to identify permanent pacemaker (PPM) predictors after transcatheter aortic valve replacement...
solaci -
Learn More
Structural heart disease

Paravalvular Leak in Surgical Prosthesis: How to Treat Them

Courtesy of Dr. Carlos Fava. The presence of paravalvular leaks (PVL) after aortic valve replacement ranges between 5%...
solaci -
Learn More
Structural heart disease

Transcaval Access: Another Alternative to Femoral Access Counterindication

For TAVR eligible patients (transcatheter aortic valve replacement) with femoral access counterindication, a new access site, extra...
solaci -
Learn More
Chronic Ischemic cardiopathy

Coronary Lesions After TAVR: Severity May Be Modified

Courtesy of Dr. Carlos Fava. Between 40% and 70% of patients undergoing transcatheter aortic valve replacement (TAVR) present coronary...
solaci -
Learn More
Structural heart disease

TAVR in Pure Aortic Insufficiency: Yes or No?

Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

AHA 2024 | VANISH2 Trial

Dr. Omar Tupayachi - 0
Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

Dr. Omar Tupayachi - 0
It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Dr. Omar Tupayachi - 0
Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy